| Companies sponsors |
Biogen (natalizumab) |
| |
Sandoz (Tyruko (natalizumab biosimilar)) |
| Others |
Department of Health and Social Care |
| |
Health Technology Wales (HTW) |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Brain and Spine Foundation |
| |
Brain Charity |
| |
MS-UK |
| |
Multiple Sclerosis Society |
| |
Multiple Sclerosis Trust |
| |
Neurological Alliance |
| |
Shift.ms |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| Professional groups |
Association of British Neurologists |
| |
British Association of Neuroscience Nurses |
| |
British Geriatrics Society |
| |
British Neuropathological Society |
| |
British Society for Blood and Marrow Transplantation |
| |
British Society of Rehabilitation Medicine |
| |
Chartered Society of Physiotherapy |
| |
Institute of Neurology |
| |
London MS-AHSCT Collaborative Group |
| |
National Neuroscience Advisory Group |
| |
Primary Care and Community Neurology Society |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Occupational Therapists |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
Therapists in MS |
| |
UK Clinical Pharmacy Association |
| |
UK Multiple Sclerosis Specialist Nurse Association |
| Associated public health groups |
Public Health Wales |
| |
UK Health Security Agency |
| Comparator companies |
Amarox (fingolimod) |
| |
Bayer (interferon beta-1a, interferon beta-1b) |
| |
Biocon Pharma (fingolimod) |
| |
Biogen Idec (interferon beta-1a) |
| |
Dr. Reddy's Laboratories (fingolimod) |
| |
Glenmark Pharmaceuticals (fingolimod) |
| |
Janssen-Cilag (ponesimod) |
| |
Merck Serono (cladribine, interferon beta-1a) |
| |
Mylan (fingolimod, glatiramer acetate, teriflunomide) |
| |
Novartis Pharmaceuticals (fingolimod, interferon beta-1a, interferon beta-1b, ofatumumab) |
| |
Roche Products (ocrelizumab) |
| |
Sandoz (fingolimod) |
| |
Sanofi Genzyme (alemtuzumab) |
| |
Sun Pharma (fingolimod) |
| |
Teva (fingolimod, glatiramer acetate) |
| |
Tillomed Laboratories (fingolimod) |
| |
Zenvita (fingolimod) |
| Evidence review group |
Bristol Technology Assessment Group, University of Bristol |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Multiple Sclerosis Society Wales |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
Neurological Alliance of Scotland |
| |
NHS Alliance |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Wales Neurological Alliance |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Brain Research UK |
| |
Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group |
| |
Cochrane UK |
| |
Genomics England |
| |
MRC Clinical Trials Unit |